European Journal of Cancer
Volume 46, Issue 18 , Pages 3400-3408 , December 2010

Interleukin-1β regulates the migratory potential of MDAMB231 breast cancer cells through the hypoxia-inducible factor-1α

  • Antonella Naldini

      Affiliations

    • Department of Physiology, University of Siena, Via Aldo Moro, 53100 Siena, Italy
    • Corresponding Author InformationCorresponding author: Tel.: +39 0577 234212; fax: +39 0577 234219.
    • ,
  • Irene Filippi

      Affiliations

    • Department of Physiology, University of Siena, Via Aldo Moro, 53100 Siena, Italy
    • ,
  • Diego Miglietta

      Affiliations

    • Department of Physiology, University of Siena, Via Aldo Moro, 53100 Siena, Italy
    • ,
  • Michele Moschetta

      Affiliations

    • Department of Oncology, Mario Negri Institute for Pharmacological Research, Milano, Italy
    • ,
  • Raffaella Giavazzi

      Affiliations

    • Department of Oncology, Mario Negri Institute for Pharmacological Research, Milano, Italy
    • ,
  • Fabio Carraro

      Affiliations

    • Department of Physiology, University of Siena, Via Aldo Moro, 53100 Siena, Italy

Received 26 July 2010 ,Accepted 28 July 2010.

References 

  1. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008;8:618–631
  2. Dinarello CA. The interleukin-1 family: 10 years of discovery. FASEB J. 1994;8:1314–1325
  3. Wilson J, Balkwill F. The role of cytokines in the epithelial cancer microenvironment. Semin Cancer Biol. 2002;12:113–120
  4. Bani MR, Garofalo A, Scanziani E, Giavazzi R. Effect of interleukin-1-beta on metastasis formation in different tumor systems. J Natl Cancer Inst. 1991;83:119–123
  5. Voronov E, Shouval DS, Krelin Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A. 2003;100:2645–2650
  6. Naldini A, Leali D, Pucci A, et al. Cutting edge: IL-1beta mediates the proangiogenic activity of osteopontin-activated human monocytes. J Immunol. 2006;177:4267–4270
  7. Saijo Y, Tanaka M, Miki M, et al. Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. J Immunol. 2002;169:469–475
  8. Suswam EA, Nabors LB, Huang Y, Yang X, King PH. IL-1beta induces stabilization of IL-8 mRNA in malignant breast cancer cells via the 3’ untranslated region: Involvement of divergent RNA-binding factors HuR, KSRP and TIAR. Int J Cancer. 2005;113:911–919
  9. Maxwell PJ, Gallagher R, Seaton A, et al. HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene. 2007;26:7333–7345
  10. Charafe-Jauffret E, Ginestier C, Iovino F, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009;69:1302–1313
  11. Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L. IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 2003;17:2115–2117
  12. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721–732
  13. Naldini A, Filippi I, Ardinghi C, et al. Identification of a functional role for the protease-activated receptor-1 in hypoxic breast cancer cells. Eur J Cancer. 2009;45:454–460
  14. Salah Z, Maoz M, Pokroy E, et al. Protease-activated receptor-1 (hPar1), a survival factor eliciting tumor progression. Mol Cancer Res. 2007;5:229–240
  15. Kasuno K, Takabuchi S, Fukuda K, et al. Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAPK and phosphatidylinositol 3-kinase signaling. J Biol Chem. 2004;279:2550–2558
  16. Buccione R, Baldassarre M, Trapani V, et al. Glycerophosphoinositols inhibit the ability of tumour cells to invade the extracellular matrix. Eur J Cancer. 2005;41:470–476
  17. Mantovani A, Marchesi F, Porta C, Sica A, Allavena P. Inflammation and cancer: breast cancer as a prototype. Breast. 2007;16:S27–S33
  18. Chirivi RG, Chiodoni C, Musiani P, et al. IL-1alpha gene-transfected human melanoma cells increase tumor-cell adhesion to endothelial cells and their retention in the lung of nude mice. Int J Cancer. 1996;67:856–863
  19. Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res. 1996;2:1843–1849
  20. Vandesompele J, De PK, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:1–12
  21. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev. 2001;81:807–869
  22. Ramjeesingh R, Leung R, Siu CH. Interleukin-8 secreted by endothelial cells induces chemotaxis of melanoma cells through the chemokine receptor CXCR1. FASEB J. 2003;17:1292–1294
  23. Boraschi D, Villa L, Volpini G, et al. Differential activity of interleukin 1 alpha and interleukin 1 beta in the stimulation of the immune response in vivo. Eur J Immunol. 1990;20:317–321
  24. Bar D, Apte RN, Voronov E, Dinarello CA, Cohen S. A continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development. FASEB J. 2004;18:161–163
  25. Chirivi RG, Garofalo A, Padura IM, Mantovani A, Giavazzi R. Interleukin 1 receptor antagonist inhibits the augmentation of metastasis induced by interleukin 1 or lipopolysaccharide in a human melanoma/nude mouse system. Cancer Res. 1993;53:5051–5054
  26. Ichijo H. From receptors to stress-activated MAP kinases. Oncogene. 1999;18:6087–6093
  27. Shin I, Kim S, Song H, Kim HR, Moon A. H-Ras-specific activation of Rac-MKK3/6–p38 pathway: its critical role in invasion and migration of breast epithelial cells. J Biol Chem. 2005;280:14675–14683
  28. Coughlin SR, Camerer E. PARticipation in inflammation. J Clin Invest. 2003;111:25–27
  29. Tsopanoglou NE, Maragoudakis ME. Role of thrombin in angiogenesis and tumor progression. Semin Thromb Hemost. 2004;30:63–69
  30. Nguyen QD, De WO, Bruyneel E, et al. Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment. Oncogene. 2005;24:8240–8251
  31. Asokananthan N, Graham PT, Fink J, et al. Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells. J Immunol. 2002;168:3577–3585
  32. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res. 2008;14:6735–6741
  33. Wolf JS, Chen Z, Dong G, et al. IL (interleukin)-1alpha promotes nuclear factor-kappaB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas. Clin Cancer Res. 2001;7:1812–1820
  34. Melisi D, Niu J, Chang Z, et al. Secreted interleukin-1alpha induces a metastatic phenotype in pancreatic cancer by sustaining a constitutive activation of nuclear factor-kappaB. Mol Cancer Res. 2009;7:624–633

☆ Financial support: MIUR (PRIN 2007) to A.N. and F.C.; PAR (Progetti 2006), University of Siena, Fondazione MPS (Grandi Attrezzature 2007), Istituto Toscano Tumori (Grant ITT 2008) to A.N.; Associazione Italiana per la Ricerca sul Cancro, Fondazione Cariplo and EU-FP7 ADAMANT (HEALTH-F2-2008-201342) to R.G.

PII: S0959-8049(10)00754-9

doi: 10.1016/j.ejca.2010.07.044

European Journal of Cancer
Volume 46, Issue 18 , Pages 3400-3408 , December 2010

Article Tools

* Image Usage & Resolution